Contact Us Site Map Request More Info
About OKTO   Eye Care Professionals   Patients   News and Press
Home     News and Press
Full Listing


AmbioDry™ Amniotic Membrane Technology Featured in November 2002 Review of Ophthalmology

COSTA MESA, California – December 1, 2002 – In the November 2002 issue of Review of Ophthalmology, the AmbioDryë Amniotic Membrane allografts were highlighted in "Amniotic Grafts Expand Surgical Options".

This Review Cover Story discusses the expanded use of human amniotic membrane in ophthalmology to treat a variety of conditions and diseases. The noted applications include pterygium excision, chemical burns; corneal ulcerations and perforations; as a substrate to support limbal cell transplants; and a biological bandage following PRK or PTK.

Stephen Plfugfelder, M.D., Director of the Ocular Surface Center at Cullen Eye Institute (Baylor College of Medicine), was interviewed for this review. "There is a body of scientific literature that suggests the stuff (amniotic membrane) is anti-inflammatory," Dr. Pflugfelder states. "It contains many of the constituents of the corneal epithelium basement membrane, and the acellular membrane to which the cornea adheres."

The article also discussed the technology features and benefits of AmbioDry. "Unlike the BioTissueís product, AmbioDry is a dehydrated, substrate-free tissue graft. It is trimmed and applied to the surgical site in its dry state, is activated with sterile saline, then sutured into place."

Dr. Pflugfelder, a world-renown corneal surgeon and researcher, is a member of the OKTO Surgical Advisory Board. He has no financial interest in OKTO or the AmbioDry technology.

OKTO Ophtho, the premier developer and distributor of specialty technologies for eye surgery, is the exclusive worldwide distributor of the AmbioDry technology.

About OKTO

Founded in 2000, OKTO Ophtho develops and commercializes specialized, leading-edge surgical technologies for eye surgery. OKTO’s purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider.

OKTO currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for ocular surface/ophthalmic reconstructive

Media Contact: